Pulmonx Corporation

As of June 30, 2026, Pulmonx Corporation carries a market capitalization of 55.83M, placing it among publicly traded companies globally. Its enterprise value stands at 56.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pulmonx Corporation's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Pulmonx Corporation has 42.95M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.62, and the price-to-book ratio stands at 1.42.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 56.20M versus a market cap of 55.83M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pulmonx Corporation maintains a current ratio of 4.32, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 143.41, indicating elevated leverage, while an interest coverage ratio of -12.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pulmonx Corporation posted a negative return on equity (ROE) of -88.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -36.74, reflecting losses generated across the asset base. The company generates approximately 296,664.97 in revenue per employee across its workforce of 294.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.23 indicates how many times Pulmonx Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pulmonx Corporation recorded 596,000.00 in income tax expense. The company reported a pretax loss of -47.52M and -48.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pulmonx Corporation's stock has gained approximately 17.50% over the past 52 weeks. The 50-day moving average sits at 2.04, while the 200-day moving average is 1.65.

Over the twelve months ended June 30, 2026, Pulmonx Corporation generated 87.44M in revenue and converted that into -48.12M in net income, yielding earnings per share of -1.15. EBITDA reached -45.39M, while operating income came in at -46.31M.

As of June 30, 2026, Pulmonx Corporation holds 55.84M in cash and equivalents against 56.21M in total debt, resulting in a net debt position of -18.31M. Total book value stands at 39.20M, with working capital of 67.73M providing operational flexibility.

Pulmonx Corporation produced -30.56M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -112,000.00 in capital expenditures, free cash flow totaled -30.67M - equivalent to -0.74 per share.

Over the twelve months ended June 30, 2026, Pulmonx Corporation posted a gross margin of 77.06, reflecting its pricing power and cost economics. The operating margin of -52.96 and net profit margin of -55.03 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -56.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -3.13, meaning Pulmonx Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Pulmonx Corporation has an Altman Z-Score of -6.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.